Pfizer (PFE) Presents Data On Utomilumab For Solid Tumors

Pfizer Inc. (NYSE:PFE) announced results from a phase Ib study on utomilumab (PF-05082566) for the treatment of advanced solid tumors.

The dose-escalation study evaluated the overall safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of utomilumab, in combination with Merck & Co. Inc.’s (NYSE:MRK) Keytruda (pembrolizumab), in patients (n~23) with advanced solid tumors including non-small cell lung cancer, renal cell carcinoma, head and neck cancers, pancreatic cancer, anaplastic thyroid cancer, small-cell lung cancer, colon cancer, sarcoma, thymoma and melanoma.

Data from the study revealed that two patients – one with small cell lung cancer and the other with renal cell carcinoma – confirmed complete response. In addition, partial responses were observed in four patients – one each with renal cell carcinoma, non-small cell lung cancer, head and neck cancer and anaplastic thyroid cancer.

Adverse events related to treatment were reported to be mild and did not appear to increase with higher doses of utomilumab. Moreover, no dose-limiting toxicity was reported. Data from the study were presented at the annual meeting of the American Society of Clinical Oncology (ASCO).

Meanwhile, utomilumab is being evaluated in several studies in both hematologic cancers and solid tumors. Utomilumab, as monotherapy, is currently being evaluated across multiple tumors. The candidate is also being evaluated in combination with Rituxan (rituximab) for the treatment of lymphoma and in combination with mogamulizumab for the treatment of advanced solid tumors.

Utomilumab, in combination with other immunotherapies, is also being studied for various solid tumors and hematological malignancies.

Pfizer currently sports a Zacks Rank #1 (Strong Buy). Bristol-Myers Squibb Company (NYSE:BMY) and ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) are two other favorably placed stocks in the health care sector, both carrying the same Zacks Rank as Pfizer.

Want the latest recommendations from Zyes i have

acks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>